Day: April 24, 2024

Ársreikningur Sveitarfélagsins Árborgar fyrir árið 2023 var lagður fram í bæjarráði og til fyrri umræðu á fundi bæjarstjórnar í dag miðvikudaginn 24.04.2024.  Rekstrarniðurstaða Sveitarfélagsins Árborg samkvæmt samanteknum rekstrarreikningi A og B hluta var neikvæð um 1.269 millj.kr. en samkvæmt samþykktri fjárhagsáætlun fyrir árið 2023 var gert ráð fyrir 1.855 mill.kr. neikvæðri rekstrarniðurstöðu. Uppfærð fjárhagsáætlun ársins 2023 gerði ráð fyrir 1.693 millj.kr. neikvæðri niðurstöðu.  Tekjur ársins af A og B hluta námu alls 17.951 millj.kr., launakostnaður 9.686 millj.kr., hækkun lífeyrisskuldbindinga nam 658 millj.kr.. Annar rekstrarkostnaður var 5.622 millj.kr. og nemur framlegð því 1.984 millj.kr. Afskriftir voru 951 millj.kr.. Fjármunatekjur, fjármagnsgjöld og tekjuskattur námu 2.302 millj.kr. og var rekstrarniðurstaða ársins því...

Press releaseParis, 24 April 2024 BUT, Conforama, MDA Company, Casino Group and Intermarché end their technical goods* purchasing partnership, Sirius Achats After almost two years, BUT, Conforama, MDA Company, Casino Group and Intermarché have decided, in accordance with the terms of their agreements, to terminate their central purchasing hub Sirius Achats with effect from 15 June 2024. Each banner can now forge new partnerships in technical goods purchasing or deepen intra-group synergies. Further to this development, MDA will remain a purchasing partner of Giga-France, the joint purchasing agency for BUT and Conforama. BUT, Conforama, MDA Company, Casino Group and Intermarché will remain committed to the same purchasing performance objectives and continue to foster the development of responsible products. * Large and small household...

Company Announcement no. 08/2024 Minutes of meeting from AGM 2024Copenhagen, April 24, 2024At cBrain’s (NASDAQ: CBRAIN) ordinary general meeting on April 24The Board of Directors’ report on the Company’s activities in the past year was approved, The Annual Report 2024 was adopted and resolution regarding discharge for the Management and the Board of Directors was passed, Appropriation of profit or covering of loss according to the approved annual report approved (dividend of DKK 0.28 per share),Peter Loft, Thomas Qvist and Per Tejs Knudsen reelected to the board andEY Godkendt Revisionspartnerselskab reelected as independent auditors.The general meeting also approved the board’s proposal for:The remuneration report for 2023, The Remuneration, Remuneration of the Board of Directors for 2023.The Board...

Amsterdam, 24 April 2024 – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, (“VEON” or the “Company”), has today announced that its Board of Directors (“Board”) has set the date for the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) for 31 May 2024. The record date for the AGM has been set for 25 April 2024. The Board and its Remuneration and Governance Committee have recommended seven individuals for appointment to the Board at the AGM, including four directors currently serving on the Board as well as nominees by statutory requisition from shareholders holding in excess of 5% of our issued share capital. The recommended nominees are Augie Fabela, Andrei Gusev, Sir Brandon Lewis, Duncan Perry, former U.S. Secretary of State Michael...

– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMFORD, Conn., April 24, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that data from the Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) will be presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 31 to June 4, 2024. SpringWorks recently initiated a rolling submission...

Press Release First quarter 2024 revenues Sales down 20% as reported Accelerating synergiesnow estimated (net of costs) at 40 million euros for 2024 and over 200 million euros from 2026 onwards GUIDANCE CONFIRMED Paris (France), April 24, 2024 – Vantiva (Euronext Paris: VANTI) today announced its unaudited sales for the first quarter of 2024. “Connected Home” sales fell by 21.7% over the quarter, despite the integration of the Home Networks business in 2024 and the contribution of the diversification activities. This is due to a strong first quarter in Q1 2023, destocking in the sector and a slowdown in capex from operators.“Supply Chain Solutions” sales were down 13.2%.Group sales totaled 458 million euros for the quarter, down 20% as reported (-19.1% at constant exchange rates). The contribution of Connected...

Not for distribution, directly or indirectly, in the United States, Canada, Australia or Japan NANTERRE (FRANCE)APRIL 24, 2024 FORVIA SUCCESSFULLY PRICES AN ADDITIONAL €200 MILLION OF 5.500% SENIOR NOTES DUE 2031 FORVIA has successfully priced its offering of €200 million of additional 5.500% senior notes due 2031 (the “New Notes”). FORVIA priced the New Notes at 101.75% of par, or a yield of 5.20%. The New Notes obtained a credit rating in line with the long-term credit rating of FORVIA (i.e. “BB+” by Fitch Ratings, “Ba2” by Moody’s and “BB” by Standard & Poor’s). FORVIA intends to use the proceeds of the offering of the New Notes to fund the repurchase in part of FORVIA’s 7.250% sustainability-linked notes due 2026 (the “Existing Notes”) in a cash tender offer (the “Tender Offer”), to pay certain fees, expenses, premiums and accrued...